This study is looking at a new way to see how well chemotherapy is working for early-stage breast cancer. It compares special mammograms called Contrast-Enhanced Digital Mammography (CEDM) and Contrast-Enhanced Digital Breast Tomosynthesis (CEDBT) with standard MRI scans. These special mammograms use an FDA-approved dye, Omnipaque 350mgI/mL Solution for Injection, to get clearer pictures. The goal is to see if CEDM+CEDBT can accurately predict how much the cancer shrinks after chemotherapy, before surgery. You may be able to join if you have locally advanced breast cancer and are planning to receive at least four cycles of chemotherapy before surgery. The study is currently unclear on its recruitment status and plans to enroll 30 women.

Study design

This is an interventional study with an unclear phase, planning to enroll 30 women. It compares two imaging methods to predict treatment effects.

What's involved

You would undergo the experimental imaging procedures, which require an injection of a contrast agent. These imaging procedures would occur immediately after definitive breast surgery.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoint, accuracy of the imaging, is measured immediately after definitive breast surgery, up to 24 weeks.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.